Home > Insider Trading > Filing (0001181431-14-002331)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
819050	Vical Inc	VICL	Biological Products, (No Disgnostic Substances) (2836)	930948554

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1198238	B Vijay Samant	10390 Pacific Center Court San Diego CA 92121	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock $.01 Par Value	Acquisiton	2014-01-10	330,000	$1.42	962,211	No	4	P	Direct
Common Stock $.01 Par Value	Disposition	2014-01-11	2,623	$1.42	959,588	No	4	F	Direct
Common Stock $.01 Par Value	Disposition	2014-01-11	7,398	$1.42	952,190	No	4	F	Direct
Common Stock $.01 Par Value	Disposition	2014-01-13	1,464	$1.34	950,726	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	F	Direct
No	4	F	Direct
No	4	F	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Nonstatutory Stock Option (right to buy)	Acquisiton	2014-01-10	500,000	$0.00	500,000	$1.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,809,000		2024-01-09	No	4	A	Direct

Footnotes

Shares were acquired pursuant to a restricted stock grant and generally vest one-third on the first anniversary of the grant, with the remainder vesting quarterly over the remaining two years.
Represents shares withheld for taxes upon the release of restricted stock granted on January 11, 2010.
Represents shares withheld for taxes upon the release of restricted stock granted on January 11, 2013.
Represents shares withheld for taxes upon the release of restricted stock granted on January 13, 2012.
This balance includes 464,450 of unvested restricted stock units.
The right to exercise the above stock option is tied to performance-based objectives relating to the timing of patient enrollment and positive data release for the Company's Phase 1/2 HSV-2 clinical trial. Mr. Samant's salary remained unchanged at 2013 levels and he received no cash bonus.